{"pmid":32167173,"title":"The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase.","text":["The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase.","An outbreak of corona virus disease 2019 (COVID-19) occurred in Wuhan and it has rapidly spread to almost all parts of the world. For coronaviruses, RNA-dependent RNA polymerase (RdRp) is an important protease that catalyze the replication of RNA from RNA template and is an attractive therapeutic target. In this study, we screened these chemical structures from traditional Chinese medicinal compounds proven to show anti-viral activity in SARS-CoV and the similar chemical structures through a molecular docking study to target RdRp of SARS-CoV-2, SARS-CoV and MERS-CoV. We found that theaflavin has a lower idock score in the catalytic pocket of RdRp in SARS-CoV-2 (-9.11 kcal/mol), SARS-CoV (-8.03 kcal/mol) and MERS-CoV (-8.26 kcal/mol) from idock. To confirm the result, we discovered that theaflavin has a lower binding energy of -8.8 kcal/mol when it docks in the catalytic pocket of SARS-CoV-2 RdRp by using the Blind Docking server. Regarding contact modes, hydrophobic interactions contribute significantly in binding and additional hydrogen bonds were found between theaflavin and RdRp. Moreover, one pi-cation interaction was formed between theaflavin and Arg553 from the Blind Docking server. Our results suggest that theaflavin could be potential SARS-CoV-2 RdRp inhibitor for further study. This article is protected by copyright. All rights reserved.","J Med Virol","Lung, Jrhau","Lin, Yu-Shih","Yang, Yao-Hsu","Chou, Yu-Lun","Shu, Li-Hsin","Cheng, Yu-Ching","Liu, Hung Te","Wu, Ching-Yuan","32167173"],"abstract":["An outbreak of corona virus disease 2019 (COVID-19) occurred in Wuhan and it has rapidly spread to almost all parts of the world. For coronaviruses, RNA-dependent RNA polymerase (RdRp) is an important protease that catalyze the replication of RNA from RNA template and is an attractive therapeutic target. In this study, we screened these chemical structures from traditional Chinese medicinal compounds proven to show anti-viral activity in SARS-CoV and the similar chemical structures through a molecular docking study to target RdRp of SARS-CoV-2, SARS-CoV and MERS-CoV. We found that theaflavin has a lower idock score in the catalytic pocket of RdRp in SARS-CoV-2 (-9.11 kcal/mol), SARS-CoV (-8.03 kcal/mol) and MERS-CoV (-8.26 kcal/mol) from idock. To confirm the result, we discovered that theaflavin has a lower binding energy of -8.8 kcal/mol when it docks in the catalytic pocket of SARS-CoV-2 RdRp by using the Blind Docking server. Regarding contact modes, hydrophobic interactions contribute significantly in binding and additional hydrogen bonds were found between theaflavin and RdRp. Moreover, one pi-cation interaction was formed between theaflavin and Arg553 from the Blind Docking server. Our results suggest that theaflavin could be potential SARS-CoV-2 RdRp inhibitor for further study. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Lung, Jrhau","Lin, Yu-Shih","Yang, Yao-Hsu","Chou, Yu-Lun","Shu, Li-Hsin","Cheng, Yu-Ching","Liu, Hung Te","Wu, Ching-Yuan"],"date":"2020-03-14T11:00:00Z","year":2020,"_id":"32167173","week":"202011|Mar 09 - Mar 15","doi":"10.1002/jmv.25761","keywords":["RNA-dependent RNA polymerase","SARS-CoV-2","theaflavin","traditional Chinese medicinal compounds"],"source":"PubMed","locations":["Chinese","RdRp","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1661359647951421441,"score":6.7365713,"similar":[{"pmid":32094225,"title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.","text":["The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.","Antiviral drugs for managing infections with human coronaviruses are not yet approved, posing a serious challenge to current global efforts aimed at containing the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including SARS-CoV and Middle East respiratory syndrome (MERS-CoV). RDV is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). Here, we co-expressed the MERS-CoV nonstructural proteins nsp5, nsp7, nsp8, and nsp12 (RdRp) in insect cells as a part a polyprotein to study the mechanism of inhibition of MERS-CoV RdRp by RDV. We initially demonstrated that nsp8 and nsp12 form an active complex. The triphosphate form of the inhibitor (RDV-TP) competes with its natural counterpart ATP. Of note, the selectivity value for RDV-TP obtained here with a steady-state approach suggests that it is more efficiently incorporated than ATP and two other nucleotide analogues. Once incorporated at position i, the inhibitor caused RNA synthesis arrest at position i+3. Hence, the likely mechanism of action is delayed RNA chain termination. The additional three nucleotides may protect the inhibitor from excision by the viral 3'-5' exonuclease activity. Together, these results help to explain the high potency of RDV against RNA viruses in cell-based assays.","J Biol Chem","Gordon, Calvin J","Tchesnokov, Egor P","Feng, Joy Y","Porter, Danielle P","Gotte, Matthias","32094225"],"abstract":["Antiviral drugs for managing infections with human coronaviruses are not yet approved, posing a serious challenge to current global efforts aimed at containing the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including SARS-CoV and Middle East respiratory syndrome (MERS-CoV). RDV is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). Here, we co-expressed the MERS-CoV nonstructural proteins nsp5, nsp7, nsp8, and nsp12 (RdRp) in insect cells as a part a polyprotein to study the mechanism of inhibition of MERS-CoV RdRp by RDV. We initially demonstrated that nsp8 and nsp12 form an active complex. The triphosphate form of the inhibitor (RDV-TP) competes with its natural counterpart ATP. Of note, the selectivity value for RDV-TP obtained here with a steady-state approach suggests that it is more efficiently incorporated than ATP and two other nucleotide analogues. Once incorporated at position i, the inhibitor caused RNA synthesis arrest at position i+3. Hence, the likely mechanism of action is delayed RNA chain termination. The additional three nucleotides may protect the inhibitor from excision by the viral 3'-5' exonuclease activity. Together, these results help to explain the high potency of RDV against RNA viruses in cell-based assays."],"journal":"J Biol Chem","authors":["Gordon, Calvin J","Tchesnokov, Egor P","Feng, Joy Y","Porter, Danielle P","Gotte, Matthias"],"date":"2020-02-26T11:00:00Z","year":2020,"_id":"32094225","week":"20209|Feb 24 - Mar 01","doi":"10.1074/jbc.AC120.013056","keywords":["Ebola virus (EBOV)","Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2","RNA-dependent RNA polymerase (RdRp), viral replicase","coronavirus, positive-sense RNA virus","drug development","enzyme inhibitor","nucleoside/nucleotide analogue","plus-stranded RNA virus","remdesivir, antiviral drug, RNA chain-termination","viral polymerase"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1661359647448104960,"score":300.49515},{"pmid":32169481,"title":"COVID-19 Spike-host cell receptor GRP78 binding site prediction.","text":["COVID-19 Spike-host cell receptor GRP78 binding site prediction.","OBJECTIVES: Understanding the novel coronavirus (COVID-19) mode of host cell recognition may help to fight the disease and save lives. The spike protein of coronaviruses is the main driving force for host cell recognition. METHODS: In this study, the COVID-19 spike binding site to the cell-surface receptor (Glucose Regulated Protein 78 (GRP78)) is predicted using combined molecular modeling docking and structural bioinformatics. The COVID-19 spike protein is modeled using its counterpart, the SARS spike. RESULTS: Sequence and structural alignments show that four regions, in addition to its cyclic nature have sequence and physicochemical similarities to the cyclic Pep42. Protein-protein docking was performed to test the four regions of the spike that fit tightly in the GRP78 Substrate Binding Domain beta (SBDbeta). The docking pose revealed the involvement of the SBDbeta of GRP78 and the receptor-binding domain of the coronavirus spike protein in recognition of the host cell receptor. CONCLUSIONS: We reveal that the binding is more favorable between regions III (C391-C525) and IV (C480-C488) of the spike protein model and GRP78. Region IV is the main driving force for GRP78 binding with the predicted binding affinity of -9.8 kcal/mol. These nine residues can be used to develop therapeutics specific against COVID-19.","J Infect","Ibrahim, Ibrahim M","Abdelmalek, Doaa H","Elshahat, Mohammed E","Elfiky, Abdo A","32169481"],"abstract":["OBJECTIVES: Understanding the novel coronavirus (COVID-19) mode of host cell recognition may help to fight the disease and save lives. The spike protein of coronaviruses is the main driving force for host cell recognition. METHODS: In this study, the COVID-19 spike binding site to the cell-surface receptor (Glucose Regulated Protein 78 (GRP78)) is predicted using combined molecular modeling docking and structural bioinformatics. The COVID-19 spike protein is modeled using its counterpart, the SARS spike. RESULTS: Sequence and structural alignments show that four regions, in addition to its cyclic nature have sequence and physicochemical similarities to the cyclic Pep42. Protein-protein docking was performed to test the four regions of the spike that fit tightly in the GRP78 Substrate Binding Domain beta (SBDbeta). The docking pose revealed the involvement of the SBDbeta of GRP78 and the receptor-binding domain of the coronavirus spike protein in recognition of the host cell receptor. CONCLUSIONS: We reveal that the binding is more favorable between regions III (C391-C525) and IV (C480-C488) of the spike protein model and GRP78. Region IV is the main driving force for GRP78 binding with the predicted binding affinity of -9.8 kcal/mol. These nine residues can be used to develop therapeutics specific against COVID-19."],"journal":"J Infect","authors":["Ibrahim, Ibrahim M","Abdelmalek, Doaa H","Elshahat, Mohammed E","Elfiky, Abdo A"],"date":"2020-03-15T11:00:00Z","year":2020,"_id":"32169481","week":"202011|Mar 09 - Mar 15","doi":"10.1016/j.jinf.2020.02.026","keywords":["BiP","COVID-19 spike","GRP78","Pep42","protein-protein docking","structural bioinformatics"],"source":"PubMed","locations":["-9.8","C391-C525"],"topics":["Mechanism"],"weight":1,"_version_":1661359647927304192,"score":290.0903},{"pmid":32181901,"title":"A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV).","text":["A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV).","During an outbreak of respiratory diseases including atypical pneumonia in Wuhan, a previously unknown beta-coronavirus was detected in patients. The newly discovered coronavirus is similar to some beta-coronaviruses found in bats, but different from previously known SARS-CoV and MERS-CoV. High sequence identities and similarities between 2019-nCoV and SARS-CoV was found. In this work, we searched the homologous templates of all nonstructural and structural proteins of 2019-nCoV. Among the nonstructural proteins, the leader protein (nsp1), the papain-like protease (nsp3), the nsp4, the 3C-like protease (nsp5), the nsp7, the nsp8, the nsp9, the nsp10, the RNA-directed RNA polymerase (nsp12), the helicase (nsp13), the guanine-N7 methyltransferase (nsp14), the uridylate-specific endoribonuclease (nsp15), the 2'-O-methyltransferase (nsp16), and the ORF7a protein could be built on the basis of homology templates. Among the structural proteins, the spike protein (S-protein), the envelope protein (E-protein), and the nucleocapsid protein (N-protein) can be constructed based on the crystal structures of the proteins from SARS-CoV. It is known that PL-Pro, 3CL-Pro, and RdRp are important targets for design antiviral drugs against 2019-nCoV. And S protein is critical target candidate for inhibitor screening or vaccine design against 2019-nCoV because coronavirus replication is initiated by the binding of S protein to cell surface receptors. It is believed that these proteins should be useful for further structure-based virtual screening and related computer-aided drug development and vaccine design. This article is protected by copyright. All rights reserved.","J Med Virol","Dong, Shengjie","Sun, Jiachen","Mao, Zhuo","Wang, Lu","Lu, Yi-Lin","Li, Jiesen","32181901"],"abstract":["During an outbreak of respiratory diseases including atypical pneumonia in Wuhan, a previously unknown beta-coronavirus was detected in patients. The newly discovered coronavirus is similar to some beta-coronaviruses found in bats, but different from previously known SARS-CoV and MERS-CoV. High sequence identities and similarities between 2019-nCoV and SARS-CoV was found. In this work, we searched the homologous templates of all nonstructural and structural proteins of 2019-nCoV. Among the nonstructural proteins, the leader protein (nsp1), the papain-like protease (nsp3), the nsp4, the 3C-like protease (nsp5), the nsp7, the nsp8, the nsp9, the nsp10, the RNA-directed RNA polymerase (nsp12), the helicase (nsp13), the guanine-N7 methyltransferase (nsp14), the uridylate-specific endoribonuclease (nsp15), the 2'-O-methyltransferase (nsp16), and the ORF7a protein could be built on the basis of homology templates. Among the structural proteins, the spike protein (S-protein), the envelope protein (E-protein), and the nucleocapsid protein (N-protein) can be constructed based on the crystal structures of the proteins from SARS-CoV. It is known that PL-Pro, 3CL-Pro, and RdRp are important targets for design antiviral drugs against 2019-nCoV. And S protein is critical target candidate for inhibitor screening or vaccine design against 2019-nCoV because coronavirus replication is initiated by the binding of S protein to cell surface receptors. It is believed that these proteins should be useful for further structure-based virtual screening and related computer-aided drug development and vaccine design. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Dong, Shengjie","Sun, Jiachen","Mao, Zhuo","Wang, Lu","Lu, Yi-Lin","Li, Jiesen"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32181901","week":"202012|Mar 16 - Mar 22","doi":"10.1002/jmv.25768","keywords":["2019-nCoV","BLAST algorithm","CLUSTAL analysis","Coronavirus","Homology modeling","MERS-CoV","SARS-CoV","Sequence alignment"],"source":"PubMed","locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1661542091970314241,"score":270.2282},{"pmid":32119961,"title":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.","text":["Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.","AIMS: A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp). MATERIALS AND METHODS: In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin. KEY FINDINGS: The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease. SIGNIFICANCE: The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection.","Life Sci","Elfiky, Abdo A","32119961"],"abstract":["AIMS: A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp). MATERIALS AND METHODS: In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin. KEY FINDINGS: The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease. SIGNIFICANCE: The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection."],"journal":"Life Sci","authors":["Elfiky, Abdo A"],"date":"2020-03-03T11:00:00Z","year":2020,"_id":"32119961","week":"202010|Mar 02 - Mar 08","doi":"10.1016/j.lfs.2020.117477","keywords":["COVID-19","Docking","Nucleotide inhibitors","RdRp","Sofosbuvir","Structural bioinformatics","Wuhan coronavirus"],"source":"PubMed","locations":["Sofosbuvir","Wuhan","Ribavirin","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647598051328,"score":261.6885},{"pmid":32159237,"title":"From SARS and MERS CoVs to SARS-CoV-2: moving toward more biased codon usage in viral structural and non-structural genes.","text":["From SARS and MERS CoVs to SARS-CoV-2: moving toward more biased codon usage in viral structural and non-structural genes.","BACKGROUND: SARS-CoV-2 is an emerging disease with fatal outcomes. In this study, a fundamental knowledge gap question is to be resolved by evaluating the differences in biological and pathogenic aspects of SARS-CoV-2 and the changes in SARS-CoV-2 in comparison with the two prior major COV epidemics, SARS and MERS coronaviruses. METHODS: The genome composition, nucleotides analysis, codon usage indices, relative synonymous codons usage (RESU) and effective number of codons (ENc) were analysed in the four structural genes; Spike (S), Envelope (E), membrane (M), and Nucleocapsid (N) genes, and two of the most important non-structural genes comprising RNA-dependent RNA polymerase (RdRP) and main protease (Mpro) of SARS-CoV-2, Beta-CoV from pangolins, bat SARS, MERS and SARS CoVs. These genes include Spike (S), nucleocapsid (N), Envelop(E) and membrane (M) genes. RESULTS: SARS-CoV-2 prefers pyrimidine rich codons to purines. Most high-frequency codons were ending with A or T, while the low frequency and rare codons were ending with G or C. SARS-CoV-2 structural proteins showed 5-20 lower ENc values, compared with SARS, bat SARS and MERS CoVs. This implies higher codon bias and higher gene expression efficiency of SARS-CoV-2 structural proteins. SARS-CoV-2 encoded the highest number of over biased and negatively biased codons. Pangolin Beta-CoV showed little differences with SARS-CoV-2 ENc values, compared with SARS, bat SARS and MERS CoV. CONCLUSION: Extreme bias and lower ENc values of SARS-CoV-2, especially in Spike, Envelope and Mpro genes, are suggestive for higher gene expression efficiency, compared with SARS, bat SARS and MERS CoVs. This article is protected by copyright. All rights reserved.","J Med Virol","Kandeel, Mahmoud","Ibrahim, Abdel Azim","Fayez, Mahmoud","Al-Nazawi, Mohammed","32159237"],"abstract":["BACKGROUND: SARS-CoV-2 is an emerging disease with fatal outcomes. In this study, a fundamental knowledge gap question is to be resolved by evaluating the differences in biological and pathogenic aspects of SARS-CoV-2 and the changes in SARS-CoV-2 in comparison with the two prior major COV epidemics, SARS and MERS coronaviruses. METHODS: The genome composition, nucleotides analysis, codon usage indices, relative synonymous codons usage (RESU) and effective number of codons (ENc) were analysed in the four structural genes; Spike (S), Envelope (E), membrane (M), and Nucleocapsid (N) genes, and two of the most important non-structural genes comprising RNA-dependent RNA polymerase (RdRP) and main protease (Mpro) of SARS-CoV-2, Beta-CoV from pangolins, bat SARS, MERS and SARS CoVs. These genes include Spike (S), nucleocapsid (N), Envelop(E) and membrane (M) genes. RESULTS: SARS-CoV-2 prefers pyrimidine rich codons to purines. Most high-frequency codons were ending with A or T, while the low frequency and rare codons were ending with G or C. SARS-CoV-2 structural proteins showed 5-20 lower ENc values, compared with SARS, bat SARS and MERS CoVs. This implies higher codon bias and higher gene expression efficiency of SARS-CoV-2 structural proteins. SARS-CoV-2 encoded the highest number of over biased and negatively biased codons. Pangolin Beta-CoV showed little differences with SARS-CoV-2 ENc values, compared with SARS, bat SARS and MERS CoV. CONCLUSION: Extreme bias and lower ENc values of SARS-CoV-2, especially in Spike, Envelope and Mpro genes, are suggestive for higher gene expression efficiency, compared with SARS, bat SARS and MERS CoVs. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Kandeel, Mahmoud","Ibrahim, Abdel Azim","Fayez, Mahmoud","Al-Nazawi, Mohammed"],"date":"2020-03-12T11:00:00Z","year":2020,"_id":"32159237","week":"202011|Mar 09 - Mar 15","doi":"10.1002/jmv.25754","keywords":["COVID-19","Codon bias.","MERS CoV","Preferred codons","SARS-CoV-2","non-structural protein"],"source":"PubMed","locations":["CoVs","Spike"],"topics":["Mechanism"],"weight":1,"_version_":1661359647864389632,"score":243.22064}]}